Developing new antipsychotic medications has proven to be a tough challenge in the biopharma world, in part because of an absence of effective biomarkers. A new study, though, concludes that the complex folds seen on the surface of the brain could provide a solid clue to how a patient suffering from ailments like schizophrenia or bipolar disorder may respond to a therapy, offering a new avenue for personalizing therapies as well as recruiting better patient populations for clinical studies. Report